Streptomyces-Derived Nano-Doxorubicin: Clinical Status and Patents Granted

    January 2024 in “ Scripta Medica
    Prabhjot Kaur, Divya Dhawal Bhandari, Hitesh Chopra
    Studysummary This review highlights the potential of nanoparticle delivery systems to mitigate doxorubicin's adverse effects and enhance its effectiveness, while discussing the integration of nanotechnology with Streptomyces-derived compounds to potentially advance future cancer therapies.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results